Cargando…
利妥昔单抗联合化疗治疗229例滤泡性淋巴瘤患者的预后研究
OBJECTIVE: To explore the clinical characteristics of follicular lymphoma (FL) in the era of rituximab combined with chemotherapy and the prognostic significance of the follicular lymphoma international prognostic index (FLIPI), follicular lymphoma international prognostic index 2 (FLIPI2), internat...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351707/ https://www.ncbi.nlm.nih.gov/pubmed/30704228 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.01.009 |
Ejemplares similares
-
苯达莫司汀联合利妥昔单抗治疗复发滤泡性淋巴瘤的临床分析
Publicado: (2022) -
硼替佐米、利妥昔单抗联合化疗治疗套细胞淋巴瘤二例报告并文献复习
Publicado: (2016) -
西妥昔单抗联合化疗治疗晚期非小细胞肺癌的临床疗效分析
Publicado: (2016) -
凝血酶原复合物联合小剂量利妥昔单抗治疗血友病B伴抑制物
Publicado: (2017) -
利妥昔单抗联合短周期、高强度方案治疗Burkitt白血病疗效及安全性分析
Publicado: (2020)